Abstract: Aspects of the present disclosure relate to polypeptides that specifically bind to a SARS-CoV-2 spike protein, and to methods of use for treatment, prevention, and diagnosis of a SARS-CoV-2 infection. Certain aspects are directed to antibodies and fragments thereof, including Fabs, configured to bind to various epitopes within the receptor binding domain (RBD) of a SARS-CoV-2 spike protein. Compositions, kits, and methods for detection of SARS-CoV-2 are also disclosed.

Abstract: The engineered polypeptide comprising modified Fab constant regions and/or protein G Fab binding domains provide advanced affinity reagents that can be used in cell biology applications as well as for therapeutic applications. Accordingly, aspects of the disclosure relate to a polypeptide comprising a constant region of an antibody light chain, wherein the constant region comprises a substitution/deletion of amino acids corresponding to positions 16-20 of SEQ ID NO:1 of the constant region with the amino acids LRT.

Abstract: Methods and compositions are provided concerning polypeptides with modifications that increase its binding affinity for the Fab region of an antibody. Methods include using the polypeptides for isolating, detecting, purifying, measuring and quantifying Fab polypeptides. Other embodiments concern kits, compositions, and solid supports containing the polypeptides and for using the polypeptides for isolating, detecting, purifying, measuring and quantifying Fab polypeptide.

Abstract: This disclosure is directed to compositions and methods for utilizing the boundaries of the C-terminal domains of Nucleoprotein from Zaire Ebola virus as highly stable recombinant protein antigens to generate antibodies for diagnosis and treatment of Ebola virus infection.

Abstract: This disclosure is directed to compositions and methods for utilizing the boundaries of the C-terminal domains of Nucleoprotein from Zaire Ebola virus as highly stable recombinant protein antigens to generate antibodies for diagnosis and treatment of Ebola virus infection.

Abstract: Methods and compositions are provided concerning polypeptides with modifications that increase its binding affinity for the Fab region of an antibody. Methods include using the polypeptides for isolating, detecting, purifying, measuring and quantifying Fab polypeptides. Other embodiments concern kits, compositions, and solid supports containing the polypeptides and for using the polypeptides for isolating, detecting, purifying, measuring and quantifying Fab polypeptide.

Abstract: Compositions and methods for delivering an agent to a cell comprising a prolactin receptor are provided. Also provided is a method of inhibiting a breast, ovarian or prostate cancer cell, where the method includes a step of contacting the cell with a complex comprising a prolactin receptor ligand linked to at least one of an RNAi-inducing agent, a polynucleotide sequence encoding a polypeptide, an miRNA, a cytotoxic moiety, a chemotherapeutic moiety, a radioactive moiety or a nanoparticle. Methods of detecting a cancer cell expressing a prolactin receptor are also provided.

Abstract: Provided herein are conjugates including a targeting vehicle coupled to an agent. The targeting vehicle includes a tachykinin receptor ligand and a reactive moiety. Conjugates including a tachykinin receptor ligand attached to an antibody or fragment thereof that is specific for an intracellular target are also provided. Also provided are methods of delivering agents to cells expressing tachykinin receptors, methods of delivering antibodies or fragments thereof to an intracellular extra-endosomal target, and methods of arresting cell growth or introducing cell death of a cancer cell.

Abstract: Provided herein are conjugates including a targeting vehicle coupled to an agent. The targeting vehicle includes a tachykinin receptor ligand and a reactive moiety. Conjugates including a tachykinin receptor ligand attached to an antibody or fragment thereof that is specific for an intracellular target are also provided. Also provided are methods of delivering agents to cells expressing tachykinin receptors, methods of delivering antibodies or fragments thereof to an intracellular extra-endosomal target, and methods of arresting cell growth or introducing cell death of a cancer cell.

Abstract: Compositions and methods for delivering an agent to a cell comprising a prolactin receptor are provided. Also provided is a method of inhibiting a breast, ovarian or prostate cancer cell, where the method includes a step of contacting the cell with a complex comprising a prolactin receptor ligand linked to at least one of an RNAi-inducing agent, a polynucleotide sequence encoding a polypeptide, an miRNA, a cytotoxic moiety, a chemotherapeutic moiety, a radioactive moiety or a nanoparticle. Methods of detecting a cancer cell expressing a prolactin receptor are also provided.